Ofri Mosenzon

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
O Mosenzon, O. Mosenzon, Ofri Mosenzon
Publication record
155 papers · 18,750 citations · H-index 44

PAPERS

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
202315 citationsauthor #3
GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS
20230 citationsauthor #7
RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
20230 citationsauthor #6
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
202310 citationsauthor #5
RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
20230 citationsauthor #4
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
202319 citationsauthor #19
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
20220 citationsauthor #9
Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
20220 citationsauthor #9
Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
20220 citationsauthor #6
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.
202226 citationsauthor #3
Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
20221 citationsauthor #5
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
20222 citationsauthor #8
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
202215 citationsauthor #4
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
20227 citationsauthor #10
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
202216 citationsauthor #5
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
202220 citationsauthor #16
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
202252 citationsauthor #8
FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
20220 citationsauthor #6
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
202252 citationsauthor #1
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
20225 citationsauthor #5
POS-676 EXPLORATORY STUDY TO ASSESS THE SAFETY OF SUBLINGUAL OIL BASED MEDICAL CANNABIS BOL-DP-O-04 IN DIALYSIS PATIENTS WHO HAVE CHRONIC PAIN
20213 citationsauthor #7
23 How physicians’ trust in their patients impacts their communication and decision-making processes
20210 citationsauthor #3
Coping with Fear of Hypoglycemia Using a Smartphone Application Combining Biofeedback and Virtual Reality
20212 citationsauthor #6
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
202112 citationsauthor #1
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
202156 citationsauthor #3
Adolescent cognitive function and incident early-onset type 2 diabetes
20219 citationsauthor #10
Asthma in Youth and Early-Onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents.
20219 citationsauthor #9
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease.
20217 citationsauthor #17
Myopia and Early Onset Type 2 Diabetes: A Nationwide Cohort Study.
202111 citationsauthor #12
Stuttering and incident type 2 diabetes: a population-based study of 2.2 million adolescents.
20218 citationsauthor #13
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
202121 citationsauthor #3
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
202120 citationsauthor #8
Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study
20210 citationsauthor #8
Adolescent Thyroid disorders and Risk for Type 2 Diabetes in Young Adulthood.
202112 citationsauthor #9
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
202153 citationsauthor #15
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
202145 citationsauthor #1
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
202185 citationsauthor #1
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
2021191 citationsauthor #1
MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58
20212 citationsauthor #5
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
202123 citationsauthor #7
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
202040 citationsauthor #8
MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
20203 citationsauthor #5
956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin
20202 citationsauthor #1
Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
20206 citationsauthor #3
Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease
20201 citationsauthor #18
278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes
20203 citationsauthor #11
Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study
202014 citationsauthor #11
Abstract 12948: Low Use of Statins in People With Type 2 Diabetes With or Without Cardiovascular Disease: A Capture Post Hoc Analysis
20200 citationsauthor #9
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58
202046 citationsauthor #3
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
2020233 citationsauthor #4
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
202013 citationsauthor #1
Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood.
202022 citationsauthor #7
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
202021 citationsauthor #2
PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE
20200 citationsauthor #18
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
20202 citationsauthor #15
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
202051 citationsauthor #4
Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
202043 citationsauthor #7
303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
20201 citationsauthor #20
TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
20203 citationsauthor #5
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel
202023 citationsauthor #8
Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents.
202017 citationsauthor #11
Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors
202093 citationsauthor #9
1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58
20201 citationsauthor #3
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease.
202038 citationsauthor #22
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
202020 citationsauthor #1
Adolescent Obesity and Early-Onset Type 2 Diabetes
2020131 citationsauthor #9
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial
202018 citationsauthor #3
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
202049 citationsauthor #3
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study
202029 citationsauthor #4
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
202026 citationsauthor #9
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
2020138 citationsauthor #10
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
20195 citationsauthor #3
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
20191,279 citationsauthor #9
OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
20190 citationsauthor #7
Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.
201914 citationsauthor #3
VERIFY the role of initial combination therapy in patients with type 2 diabetes.
20196 citationsauthor #1
244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial
201912 citationsauthor #19
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
20192,265 citationsauthor #7
1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
20196 citationsauthor #1
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
2019440 citationsauthor #3
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
2019110 citationsauthor #5
410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus
20190 citationsauthor #5
Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood
201927 citationsauthor #8
Einfluss der Dosisanpassungsmethode bei Verwendung von schnell wirksamem Insulin aspart (Faster aspart) auf die Blutzuckereinstellung bei Typ 1 Diabetes: eine Post-hoc-Auswertung der Studie onset® 8
20190 citationsauthor #8
ESICON 2019 Abstracts
20194 citationsauthor #150
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
201932 citationsauthor #5
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
20194,545 citationsauthor #4
NATRIURETIC PEPTIDES VERSUS A CLINICAL HISTORY OF HEART FAILURE FOR RISK PREDICTION IN PATIENTS WITH DIABETES
20191 citationsauthor #6
Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
20192 citationsauthor #3
Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
201943 citationsauthor #5
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
2019253 citationsauthor #5
Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide: Unveiling Anaphylaxis to Glucagon-Like Peptide 1 Receptor Agonists
201921 citationsauthor #3
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
2019571 citationsauthor #8
Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
201946 citationsauthor #5
236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial
20190 citationsauthor #1
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
2019571 citationsauthor #1
Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
20195 citationsauthor #3
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
2019271 citationsauthor #1
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
2019113 citationsauthor #2
Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
20191 citationsauthor #3

TIMELINE

2012 5 citations

2013 3,327 citations

2014 245 citations

2015 854 citations

2016 566 citations

2017 164 citations

2018 1,080 citations

2019 10,648 citations

2020 1,087 citations

2021 569 citations

2022 196 citations

2023 44 citations

Ofri Mosenzon

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT